Circulating microparticles: square the circle

Natasha S Barteneva1,2*, Elizaveta Fasler-Kan3,4, Michael Bernimoulin5, Joel NH Stern6, Eugeny D Ponomarev7,8, Larry Duckett9 and Ivan A Vorobjev10

Abstract

Background: The present review summarizes current knowledge about microparticles (MPs) and provides a systematic overview of last 20 years of research on circulating MPs, with particular focus on their clinical relevance.

Results: MPs are a heterogeneous population of cell-derived vesicles, with sizes ranging between 50 and 1000 nm. MPs are capable of transferring peptides, proteins, lipid components, microRNA, mRNA, and DNA from one cell to another without direct cell-to-cell contact. Growing evidence suggests that MPs present in peripheral blood and body fluids contribute to the development and progression of cancer, and are of pathophysiological relevance for autoimmune, inflammatory, infectious, cardiovascular, hematological, and other diseases. MPs have large diagnostic potential as biomarkers; however, due to current technological limitations in purification of MPs and an absence of standardized methods of MP detection, challenges remain in validating the potential of MPs as a non-invasive and early diagnostic platform.

Conclusions: Improvements in the effective deciphering of MP molecular signatures will be critical not only for diagnostics, but also for the evaluation of treatment regimens and predicting disease outcomes.

Keywords: Circulating, Microparticles, Exosomes, Microvesicles, Disease, Diagnostics, Therapy

Background

The present review summarizes information concerning microparticles (MPs), covering the clinical aspects of circulating MPs, recent advances and technological developments in this field.

Implementation

Several recent reviews have concentrated on specific aspects of cellular vesicles biology, focusing primarily on exosomes (subset of cellular vesicles with size < 100 nm) and the mechanisms involved in cellular vesicles release and signaling [1-6]. This review focuses on another subset of cellular vesicles, i.e. microparticles (MPs). MPs are sub-micron vesicular fragments of cells that can be released by diverse eucaryotic and procaryotic cells and multicellular organisms under conditions of stress/injury [7-9]. Although novel methods to identify and characterize MPs have been developed in the last decade, classification of MPs, understanding of the molecular mechanisms of their release and biological function are still under intensive scrutiny [10-14]. The aims of this review article are to provide i) a systematic overview on circulating MP biology, and ii) a comprehensive description of the role of MPs in different diseases, based on the analysis of over 200 publications addressing changes in circulating MPs during pathological processes.

Results and discussion

MPs: attempts to define

MPs are described as a heterogeneous population of membrane-delimited vesicles 50–1000 nm in size released from the cells in which they form and retaining certain antigens of their cells of origin [8,14,15]. MPs could be distinguished from other groups of cell-derived vesicles such as exosomes and apoptotic bodies. Exosomes are small vesicles (40–100 nm) that form through constitutive exocytosis of multivesicular endosomes [4,8], and often contain endocytic markers, such as tetraspannins and HSP73 [2,16]. MPs (also called “ectosomes”) form mostly by reverse budding and fission of the plasma membrane [17]. Because exosomes and MPs are often released concomitantly, differentiation of these two microvesicular species is difficult [18].
The size of MPs (50 to 1000 nm), their lipid composition, and their irregular shape and density are major parameters that separate them from exosomes (usually of diameter < 100 nm and lower density – 1.13-1.19 g/mL) and apoptotic bodies (much larger vesicles released at the final steps of apoptosis and normally 1000–3000 nm in size) [8,19]. This variance in reported size of MPs could occur due to limitations in the methods of the detection of MPs and differences in MP purification protocols, such as the anticoagulant used, centrifugation speed, filtration conditions, and type of storage used [20,21]. Besides, the majority of MPs express on their surface phosphatidylserine (PS) whereas PS is usually absent from exosomes’ surface [22]. In general, exosomes are smaller than MPs; however, reported sizes of MPs vary by publication, ranging from 50 nm to 1000–2000 nm (Additional file 1) and thus it is better to say that different research protocols allows one to enrich preparations with certain type of vesicles but not to separate different research protocols allows one to enrich preparations with certain type of vesicles but not to separate them as a pure fraction. Current nomenclature of cell-derived vesicles was exhaustively presented recently [8], and we will follow it using terms microparticle and microvesicle as synonyms.

### Methods of MPs characterization

Isolation of MPs typically involves a combination of centrifugation and size-based filtration followed by characterization using flow cytometry, electron microscopy, Western blotting or proteomics. Isolation of MPs from the peripheral blood of patients or healthy controls starts with drawing blood into the tubes with different anticoagulants: sodium citrate, acid-citrate-dextrose, EDTA salt, or heparin. Sodium citrate is the most widely used anticoagulant [23]; however, blood collected with sodium citrate usually gives significantly lower levels of PS-positive MPs than blood collected in heparin [24]. Centrifugation is a critical step as well, since it can induce additional shedding of MPs from some cell types [24–26]. It is also possible that MPs can fuse during preparation, as MPs isolated by centrifugation are somewhat bigger than MPs in native MP-containing biological samples [27]. Haemolysis during sample preparation can significantly affect the amount of MPs isolated from plasma, as well as amounts of MP-related molecules like miRNA [28]. The size distributions of platelets (2–3 μm) and MPs (up to 2 μm) partially overlap, and current consensus indicates that the best way to remove contaminating platelets from MP preparations is via filtration. However, filtration of MPs should be used with caution, since this procedure can lead to fragmentation of larger MPs [29]. Finally, storage of purified MPs even at −80°C may further modify their characteristics [24,30].

Research focused on elucidating MP composition and functional activity is hampered by the complexity of the biological fluids where MPs are present and the small size of MPs [31]. Electron microscopy (EM) gives the diameter of individual MPs, but does not always provide quantitative data on the MP population - particularly when negative staining or cryoelectron microscopy are used. On ultrathin sections MPs appear as single, membrane-bounded vesicles with diameters ranging between 20–40 nm [32-35] and 300–700 nm [36–42], with the larger MPs exhibiting heterogeneous internal content. MPs as large as 1 μm in diameter were described using freeze-fracture and scanning EM [32-35]. Besides EM, atomic force microscopy and dynamic light scattering have been used for MP characterization [21,27,29,31].

The protein content of MPs is usually ascertained by Western blotting and proteomic approaches [43,44]. These assays require large numbers of MPs, limiting their utility for translational studies that require serum or other bodily fluids [45]. To date, only flow cytometry and microscopy methods have proved capable of providing specific information on the presence or absence of specific antigens in MPs derived from limited amounts of material. The application of different methods to exosome and MP research has been summarized by Van der Pol and coauthors [8,31,46], and in a number of recent publications [21–24,47,48].

Current flow cytometry methods utilize both fluorescence probes and light scattering. Quantification of MPs by flow cytometry shows good correlation with the relative light scattering intensities determined by dynamic light scattering [49]. There are also indirect approaches for MP enumeration based on their functional activities [50,51]. However, conventional flow cytometry light scattering has size limitations and usually not able to detect microvesicles with diameters smaller than 300–400 nm as a separate fraction [31,52]. Particle size can be directly measured using impedance-based Coulter-type cytometers, but the sensitivity of this technology is also limited by 300–500 nm [31,52,53]. One other widely employed cytometric approach for the identification and characterization of MPs involves the use different sized beads as references [53,54]. However, the refractory index of polystyrene or other synthetic beads is higher than that of MPs, thus signals generated by MPs are very small. While conventional cytometers equipped with a photodiode for measuring forward light scatter have significant limitations in sensitivity for MP analysis, cytometers equipped with a photomultiplier in the forward scatter channel allow for better resolution of MP fractions (Figure 1, SORP FACSAria (BD Biosciences, San Jose, USA)). MPs can be directly stained with fluorescent antibodies and with fluorescent lipophilic dyes, both of which dramatically increase the ability of the cytometer to separate MPs from debris. For the best detection, MP staining for flow cytometry should include a lipid marker such as calcein AM, PKH67, or bio-maleimide [54–56], since...
staining MPs with only specific antibodies (AB) or annexin V can leave a significant percentage of MPs unstained or poorly stained and, as a result, lead to underestimation of MP levels. Recently, investigators have begun to use flow image cytometry for MP characterization (Figure 2). The advantages and disadvantages of commonly used methods for MP quantification and characterization are summarized in Table 1.

**Origin of MPs**

MPs have been identified in human plasma, peripheral blood, cord blood, urine, saliva and cerebrospinal fluid.
| Method                                      | Quantification | Cell origin and/or function identification | MPs size distribution | Limitations                                                                 | References                                                                 |
|---------------------------------------------|----------------|---------------------------------------------|-----------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Electron microscopy                         | Limited        | Limited (only for single labeling by immunoelectron microscopy) | Yes, but might be subjective due to limited number of measurements | Artifacts due to specimen preparation for negative contrast (drying, application of contrasting solution etc.) | Hess et al., 1999; Distler et al., 2005; Lima et al., 2009; Witek et al., 2009; Porro et al., 2010; Duarte et al., 2012; Gercel-Taylor et al., 2012 |
| Functional assays (procoagulant activity, thrombin generation tests, ELISA-based tests etc.) | Yes (bulk)     | No                                          | No                    | Only information on procoagulant or thrombin generating activity available | Leroyer et al., 2007; Tesselaar et al., 2007; Salzer et al., 2008; Manly et al., 2009; Van der Heyde et al., 2011 |
| Atomic Force Microscopy                     | Limited        | Limited (requires development of AB-coated surfaces) | Yes, but might be subjective due to limited number of measurements | Artifacts due to abundance of cell debris and plasma protein | Salzer et al., 2008; Yuana et al., 2010; Leong et al., 2011; Nantakomol et al., 2012 |
| Light scattering techniques (nanoparticle tracking analysis, submicron particle analysis, dynamic light scattering) | Yes            | No*                                         | Yes                   | Artifacts due to abundance of cell debris and plasma protein – samples requires special purification | Lawrie et al., 2009; Xu et al., 2010; Gercel-Taylor et al., 2012 |
| Western blotting                            | Semi-quantitative | Yes                                         | No                    | Requires significant amount of starting material (> 10 μg of vesicular material) | Abid Hussein et al., 2005; Salzer et al., 2008; Sander et al., 2008; Bebawy et al., 2009; Bernimoulin et al., 2009; Gercel-Taylor et al., 2012 |
| Mass-spectrometry                           | No             | Yes, allows identification of multiple proteins | No                    | Requires significant amount of starting material | Sander et al., 2008; Mayr et al., 2009; Rood et al., 2010 |
| Flow Cytometry                              | Yes            | Yes, allows identification of multiple antigens | Limited               | Limited; >300 nm particle range (conventional flow cytometry); presence of protein aggregates may lead to artifacts sensitivity depends on cytometer | Orozco, Lewis, 2010; Zwicker et al., 2010; Ayers et al., 2011; Yuana et al., 2011; van der Heyde et al., 2011 |
| Flow imaging cytometry                      | Yes            | Yes, allows quantification of multiple antigens | No                    | Limited for bright fluorescence MPs | Van der Heyde et al., 2011 |

*custom modified NTA system allows limited number of fluorescent measurements (Gercel-Taylor et al., 2012).

**References for Table 1 (Additional file 2).
[45,57-62]. In addition, MPs have been found at different sites in lung disease patients [39], and in bronchoalveolar lavage fluid (BALF) from patients with acute respiratory distress syndrome or hydrostatic pulmonary edema [63,64]. MPs have also been described in human atherosclerotic plaque [65-67], ascites, postoperative drainage fluid, and chylous fluid [41], as well as in immunologically privileged sites such as vitreous eye liquid and synovial liquid [68-72]. Large body of evidence suggests that MPs are derived from all cellular types. The origin of MPs is critical because MPs with similar shapes and diameters yet derived from different cell types possess unique functional capabilities. Aleman et al. showed that MPs (100–300 nm in size) derived from monocytes had higher ability to support clot formation, making it more dense and stable compared to PMPs [73]. It has long been thought that the majority of MPs in the peripheral blood of a healthy person are released from platelets and endothelial cells [24,74]. However, it was recently suggested that CD61-positive MPs (currently called "PMPs") originate directly from megakaryocytes [75,76]. Rank et al. showed that patients undergoing hematopoietic stem cell transplantation after total body irradiation (12 Gy) exhibit a rapid decline of the level of peripheral blood MPs, with CD61+ MPs disappearing faster than platelets and MPs expressing CD63 or P-selectin, leading the authors to conclude that at least a fraction of CD61+ MPs originate from megakaryocytes [77].

To characterize the cellular origin of MPs in peripheral blood, the most common approach is to stain MPs with fluorescently-labeled AB directed against antigens of parental cells (for example CD41, CD61 and platelet-activation marker CD62 for platelets; glycophrin for erythrocytes; CD45 for lymphocytes; CD14 for monocytes; and so on) and to perform subsequent analysis by flow cytometry. However, a large variety of CD markers have been used by different groups to characterize background and activation of MPs derived from endothelial cells (CD31, CD34, CD62E, CD51, CD105, CD144, CD146) versus platelets (CD41, CD41a, CD42a, CD42b, CD61, CD62P) may have led to inconsistency in the functional characterization of MPs populations (reviewed in [15]).

**Shedding (ectocytosis) and MP content**

Though MP shedding is enhanced upon cell activation, constitutive ectocytosis is a permanent ongoing process in vivo for the majority of cells and significant levels of MPs originating from different cells can be always found in the plasma [78,79]. MPs contain a wide range of biomolecules: proteins (signal proteins and receptors, cytoskeleton and effector proteins), lipids, and nucleic acids, (e.g. microRNA, mRNA, and even DNA). MP surface protein content may be different from that of the plasma membrane of the cell of origin, as the incorporation of protein molecules into MPs can be a selective and modulated by agonist activators and/or microenvironments of the parental cells [54,80-84]. Depending on the stimulus, the protein content of MPs derived from the same cell lineage can vary. Jimenez et al. [85] demonstrated that endothelial cells release qualitatively and quantitatively distinct MPs in response to TNF-α (activation stimulus) and upon the induction of apoptosis by growth factor deprivation. In addition, several groups performing MP proteomic profile studies have found that characteristics of MPs isolated from peripheral blood depend on the type of stimulus used for their generation [54,86]. It has been shown that the density of β2-integrin and P-selectin is markedly enhanced in platelet-derived MPs (PMPs), whereas MPs from activated neutrophils are highly enriched in activated Mac-1 (10-fold enrichment) [87,88]. Moreover, the surface of PMPs is 50 to 100-fold more procoagulant than the surface of activated platelets [87]. It is likely that specific protein enrichment of MPs membrane is due, at least in part, to lateral re-organization of membrane lipids into cholesterol-rich lipid rafts during MP shedding [89,90]; however, the exact mechanisms involved in this process requires further investigation.

Plasma membrane remodelling is a critical event during apoptosis and cell activation, and enzymes that regulate this process also regulate MP production [14]. The formation of MPs in response to activating stimuli is initiated by an agonist-mediated increase in intracellular calcium (Figure 3a), activation of kinases and inhibition of phosphatases, and calpain activation [14]. Activation of calcium-dependent scramblase (an ATP-independent transporter) and floppase (an exofacially-directed, ATP-dependent transporter) [91] results in exposure of PS on the outer leaflet of the plasma membrane [92]. Levels of PS exposure depend on the type of stimulation [85,93-95]. However, in some cases the processes of PS exposure and MP generation can be separated [96]. Particularly in endotoxemia and sickle cell disease formation of a large number of annexin-negative MPs was described [97,98]. Concomitant with the exposure of PS on the outer leaflets of MP membranes, calcium-sensitive enzymes such as calpain and gelsolin are activated, which promotes subsequent vesiculation [99]. In addition to the pathways described above, MP formation and trafficking can occur via ARF6-regulated endosomal pathways [100]. The exact mechanisms of lipid scrambling, PS exposure on the outer membrane leaflet, and ultimately MP formation, can differ between cell types [101,102]. In any case, PS on the surface of MPs is an important factor in mediating their functional activity: PS acts as a major prothrombotic and procoagulation signal, enhancing activation of coagulation proteins, TF, and platelet aggregation [103]. The functional role of
PS-negative MPs is still a subject of debate, though elevated levels of circulating Annexin-negative MPs had been reported for initial phase of stroke, systemic lupus erythematosus (SLE) and some other diseases [104-107]. MPs can be captured by PS-binding molecules like T-cell immunoglobulin domain and mucin domain proteins, which are expressed on the surface of activated lymphocytes and phagocytes [108,109]. Formation and/or release of MPs can also be influenced by apoptotic signals [110] (Figure 3b). The shedding of MPs in response to apoptotic stimuli critically depends on the activation of Rho-associated kinase ROCK1 [111].

Several other enzymes possibly involved in MPs formation and activity include aminophospholipid translocase, and other members of the floppase family, as well as protein disulfide isomerase (PDI) – enzyme modulating flipase and floppase activities and regulating coagulation on endothelial cells [112] was shown to be a component of MPs released during tissue factor (TF)-dependent thrombosis [113]. Recently, Bianco et al. [114] demonstrated that activation of acid sphingomyelinase is necessary and sufficient for MP release by glial cells. As mentioned above, it is likely that lipid rafts are important participants in MP formation, since the depletion of plasma membrane cholesterol or raft disruption by methyl-cyclodextrin reduces MP release from a variety of cell types [89,115,116].

Enhanced release of MPs is associated with diverse stimuli including hormones, fatty acids, reactive oxygen species (e.g. hydrogen peroxide) [117], increased intracellular calcium levels [99]. Increased MP output is also driven by signals transduced through specific activating receptors, such as the purinergic receptor P2X on monocytes and neutrophils, thrombin receptors on platelets, and Toll-like receptor 4 (TLR4) on dendritic cells [118]. The level of MPs in human plasma can increase or decrease in response to different hormones, such as progesterone, estradiol, estrogen, insulin and others [119-121]. For example, low levels of estrogen in the blood are associated with increased microvesiculation and MP release [122]. Treatment with glucocorticoids significantly decreases the level of PMPs in peripheral blood in patients with polymyositis or dermatomyositis [123]. While insulin may promote MP release in certain cases, it has been found to reduce the procoagulant activity of MPs derived from lipopolysaccharide (LPS)-activated monocytes [124].

MPs also carry all types of nucleic acid molecules, including mRNA and DNA fragments [125,126]. Risitano et al. [127] demonstrated that platelet-derived mRNA could be transferred by MPs to monocytes and endothelial cell lines and undergo translation in the recipient cells. Improved ability to detect low copy numbers of small RNAs, including miRNA, has rapidly advanced the MP field, since these molecules has to be protected from plasma nucleases and may be functional only when had been transferred by MPs internalized by target cells. Indeed, MPs from healthy donors contain miRNAs that have different functional activities [128], such as regulation of hemostasis [129]. Diehl and coauthors [130] assessed miRNA profiles of MPs derived from stimulated and non-stimulated endothelial cells (THP-1 and HUVECs) and found that miRNA profiles of MPs differed from those found in the stimulated or non-stimulated parental cells (some miRNAs upregulated while others down-regulated),

![Figure 3 Basic scheme of MP formation via reverse budding. A. Activated cells release MPs in response to Ca^{++} agonists. Increased concentration of Ca^{++} alter the asymmetric PS distribution of the plasma membrane, activate kinases, inhibit phosphatases and activate calpain, which leads to reorganization of cytoskeleton and increased MPs production. B. MP formation during the early stages of apoptosis is associated with GTP-bound Rho proteins, which activate the ROCK-I kinase. This kinase is involved in cortical myosin-II contraction, detachment of the plasma membrane from the cytoskeleton, and release of MPs that have hijacked cytoplasmic components, nucleic acids, and membrane antigens.](image)
suggesting a process of selective miRNA packaging into MPs. Specifically, MPs derived from stimulated THP-1 cells contained increased inflammatory miRNA and induced inflammation markers up-regulation in non-stimulated cells [130].

**Functional activities of MPs: interaction with homologous or heterologous cells**

As outlined above, MP production is a tightly regulated and selective process, suggesting that MPs may be important mediators of cell-to-cell communication. MPs can be internalized in a dose-dependent manner by macrophages, endothelial cells and other cell types (an example of MP internalization by hCMEC/D3 cells is shown in Figure 4). MP internalization can influence both functional and phenotypic characteristics of target cells. MPs may operate via surface interactions with receptor molecules on target cells or, more importantly, by directly transferring their contents, including RNA [130-133], bioactive lipids (for example platelet-activating factor (PAF) and PAF-like lipids), and proteins into the recipient cell [134,135].

The MPs express adhesion molecules on their surface, which may influence the probability of their capture by target cells and mediate MPs effects on cell behavior [136-138]. The cellular origin and site of release are essential factors in determining the functional activities of MPs. For example, MPs derived from red blood cells, but not from blood polymorphonuclears (PMNs) inhibit activation of macrophages by zymosan and LPS [139,140]. MPs participate in the release of insoluble proteins such as transmembrane receptors (CCR5, TF, EGFR, etc.) [90,141,142] and other surface molecules involved in immunomodulation [118,143,144]. The transfer of membrane-anchored receptors by MPs results in phenotypic alteration of the recipient cell, making it susceptible to different activating stimuli. For example, transfer of the chemokine receptor CCR5 by MPs to CCR5-deficient peripheral blood mononuclear cells makes them more sensitive to infection by CCR5-tropic HIV viruses [141]. Shuttling of the chemokine receptor CXCR4 by MPs contributes to HIV disease progression, since CXCR4 also serves as a co-receptor for some viruses [145]. Besides transferring receptor molecules, MPs may transfer chemokines, cytokines and growth factors to target cells [90,146]. For example, MPs transfer pro-apoptotic arachidonic acid between endothelial cells and circulating angiogenic cells [147], and constitute a main reservoir of blood-originated TF, the main activator of blood coagulation [142].

Lung-derived MPs have been shown to transfer mRNA to marrow cells [148], and MPs derived from endothelial progenitor cells have been reported to carry a wide range of mRNAs and to promote angiogenic activity and proliferation in quiescent endothelial cells [149]. Hemopoietic stem cell-derived MPs contain mRNAs that contribute to the reprogramming of target cells [150]. Transfer of mRNAs to hepatocytes by liver stem cell-derived MPs induce proliferation and resistance to apoptosis [151]. Yuan et al. [152] demonstrated that miRNAs that are highly enriched within MPs are transferred to mTEC cells via MP internalization. miRNAs shuttled by MPs have been shown to downregulate the activity of proteins participating in cell proliferation and apoptosis such as cyclin D1, Bcl-2 and PTEN [153]. The most abundantly expressed miRNA in plasma MPs is miR-223, which participates in the maturation, proliferation and differentiation of myeloid and lymphoid cells [128]. MPs may also assist in the delivery to target cells of synthetic miRNAs [153].

A growing body of evidence supports an important role for MPs in the induction of apoptosis. MPs released at the early stages of apoptosis do not contain organelles and their size is smaller than 1 μm; however, they sediment at a lower acceleration than exosomes [110]. In contrast, so-called “apoptotic bodies”, which are released during the final stages of apoptosis, have a size of 1–4 μm, and often contain organelles [144]. Recently, Sarkar et al. [154] have demonstrated that monocyte-derived MPs induce death of target cells by delivering caspase-1. MPs from endothelial cells and platelets may also contain active executive caspase-3 [155–157]. Similarly, tumor-derived MPs serve as circulating cargos for Fas ligand (FasL or CD95L), and therefore induce apoptosis in lymphoid target cells harboring the Fas receptor [158,159]. In addition to FasL, MPs and exosomes from different human tumors (melanoma, head, neck, ovary, colorectal and other cancers) may carry other proapoptotic molecules, such as TRAIL [143,159-161].

**Figure 4** An epifluorescence microscopy image shows that hCMEC/D3 cells have internalized small MPs (arrowheads), which had been purified from human glioma cells treated with TRAIL (100 units/ml) and stained with PKH-67 (Sigma, USA) before addition to the hCMEC/D3 cells. MPs that are attached to the cell surface are out of focus (representative photo from Z-stack collection). Objective Plan Apo x60/1.4. Bar 5 μm.
Circulating MPs

The level of circulating MPs depends on the balance between their rates of formation and clearance. Clearance of MPs occurs through several main mechanisms. The major one is degradation due to the action of phospholipases and proteases [162]. Other potential routes of MP clearance include: (i) opsonization with subsequent phagocytosis; (ii) uptake of MPs from the circulation by liver Kupffer cells in a PS-dependent manner [163]; (iii) phagocytosis of MPs by splenocytes [164]; and (iv) uptake of MPs by the lung macrophages [165]. In a rat model, both the spleen and liver were found to participate in the clearance of MPs labeled with radioactive $^{51}$Cr, with only 12% of injected erythrocyte-derived microvesicles retained in the plasma after 60 min [166]. However, recent studies suggest that survival of PS+ MPs in human blood is rather long: the half-life of Annexin V+-MPs measured upon transfusion of apheresis platelet concentrates is approximately 5.8 hours and for CD61+ MPs it is 5.3 hours [167]. MP size is also an important factor in their clearance — strong inverse correlation between IgM-mediated clearance half-time and particle size of MPs by macrophages was determined [168]. On opposite, Al-Faraj et al. [169] demonstrated rapid clearance (within 5 min) of iron-labeled MPs by time-lapse molecular imaging using mouse model. However, it should be taken into account that labeling of such a fragile thing as MPs \textit{ex vivo} may change clearance characteristics and kinetics.

While low MP concentrations can be detected in the blood and body fluids of healthy subjects [170-172] (summarized at Table 2), increased concentrations of MPs in the blood of patients with different pathological states supports the notion that MPs play a role in numerous diseases, including different cancers (Table 3), infectious diseases, autoimmune diseases, thromboembolic events and others (Table 4). However, most of these studies are observational and the possible role of MPs as prognostic biomarkers in stratification of disease risk groups is only starting to be addressed. There have been very few prospective studies aimed at evaluating whether there is an association between the quantities of a certain subtype of MP (endothelial, erythrocyte or other cell-derived MPs) and the outcome of diseases or therapeutic procedures [173-175]. Increased MP levels in pathological disorders such as intracerebral hemorrhage, endotoxemia, hepatitis C and others are generally associated with adverse outcomes (Additional file 3), and high levels of MPs associated with these disorders could, at least partly, be implicated in the vascular complications of these diseases. However, although increased levels of circulating MPs have been associated with various autoimmune diseases (SLE, rheumatoid arthritis, systemic sclerosis), facile correlation of MP quantity and adverse outcomes is complicated by the fact that plasma MP levels appear to increase to lower levels in patients with more severe disease [176]. Thus, the factors regulating MP release during disease progression are complex and yet remain to be evaluated. In this regard, it is important to consider the effect of pharmacological agents on circulating MP levels and their composition (summarized in the Additional file 4). Most of these studies have demonstrated that beneficial treatment of disease lowers circulating MP levels. For example, treatment of multiple sclerosis (MS) with interferon-β1 decreased the amount of...

### Table 2 MPs levels in the plasma of healthy controls

| Disease                        | MPs plasma levels                                      | Reference                                                                 |
|-------------------------------|--------------------------------------------------------|---------------------------------------------------------------------------|
| Cord blood                     | Elevated MP levels or activity comparing with mother’s plasma | Uszynski et al., 2011; Schweintzger et al., 2010; 2011                     |
| Healthy smokers                | Elevated EMPs levels; Diminished MP levels             | Gordon et al., 2011; Grant et al., 2011                                    |
| Healthy donors                 | MP levels                                              | Berckmans et al., 2001; Bretelle et al., 2003                             |
| Normal pregnancy               | Elevated MP levels                                     | Bretelle et al., 2003                                                     |
| Strenuous physical exercise    | Elevated PMPs and PMN-MPs                              | Chaar et al., 2011                                                        |
| Gender                         | Elevated CD61+ MPs in men; no difference               | Caby et al., 2005; Toth et al., 2007; Grant et al., 2011                  |
| Climacteric                    | Lowered PMPs levels, no impact on EMPs levels          | Rank et al., 2012                                                         |
| Age (<18 years)                | Elevated MP levels                                     | Proulle et al., 2005                                                      |
| Age (geriatric patients)       | Decrease EMPs, altered MP response to infection         | Forest et al., 2010                                                       |
| High-fat meal                  | Elevated cycling blunts of CD18+ and CD11a+ MMPs and EMPs levels | Strohacker et al., 2012                                                   |
| Obesity                        | Elevated MP levels; elevated CD144+EMP s               | Goichot et al., 2006; Esposito et al., 2006; Gunduz et al., 2012           |
| Endotoxemia (E.coli LPS) in healthy volunteers | Elevated TF+ MPs                                       | Aras et al., 2004; Woei-A-Jin et al., 2012*                              |

*References for Table 2 (Additional file 5).
circulating CD31+ endothelial MPs in plasma [177]. Similar results were obtained by Lowery-Nordberg et al. [178]. These data suggest that the quantity of specific MPs in the circulation may be used as a surrogate marker for interferon therapy responsiveness.

The association of elevated levels of certain MP subtypes with specific disease states may also have therapeutic implications. An interesting possibility is the use of *in vitro* generated MPs to stimulate neovascularization in the diseases with impaired angiogenesis [179], while a different subset of MPs could be used to inhibit tumor-induced angiogenesis and, possibly, even tumor development [180]. Therapeutic strategies to reduce severity of disease may also decrease the level of circulating MPs. Thus, the level of platelet-derived MPs in diabetic patients is decreased after treatment with antioxidants such as vitamin C [181] or miglitol [182]. La Vignera et al. [183] showed that endothelial-derived MP (EMPs) level is significantly decreased in patients with erectile dysfunction [184].

| Disease                          | MPs plasma levels                                                                 | Reference                                                                 |
|----------------------------------|----------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Acute myeloid leukemia           | Elevated MPs levels; decreased during chemotherapy and increased during remission; elevated CXCR4+- MPs; elevated PMPs and myeloblast-derived MPs | Kalinkovich et al., 2006; Szczepanski et al., 2011; Van Aalderen et al., 2011 |
| Acute lymphoid leukemia          | MPs in bone marrow aspirate                                                      | Savasan et al., 2004                                                     |
| Acute promyelocytic leukemia     | Elevated CD33+TF+ MPs                                                           | Ma et al., 2013                                                          |
| B-cell chronic lymphoid leukemia | Elevated MPs levels                                                              | Ghosh et al., 2009                                                       |
| Bladder cancer                   | Elevated MPs containing EGFR-associated proteins                                 | Smalley et al., 2008                                                    |
| Brain cancer                     | TF+ MPs not elevated                                                             | Thaler et al., 2012                                                     |
| Breast cancer (getting endocrine therapy) | Elevated MPs levels; elevated annexin V+, CEA+, BCRP+, HSP27+ subpopulations of MPs | Liebhardt et al., 2010; Trappenburg et al., 2011                         |
| Breast cancer (metastatic)       | Elevated TF+ MPs levels; elevated PMPs and annexin V+-MPs; increased annexin V+, CD66+, BCRP1+ and HSP27+ MPs | Tesselaar et al., 2007; Toth et al., 2008; Liebhardt et al., 2010         |
| Colorectal cancer                | Elevated TF+ MPs levels                                                          | Hron et al., 2007                                                        |
| Gastric cancer                   | Elevated MPs and PMPs levels                                                      | Kim et al., 2003; Baran et al., 2010                                     |
| Glioblastoma multiforme          | Elevated procoagulant MPs                                                        | Sartori et al., 2011                                                    |
| Gynecological cancer             | MPs levels are not elevated                                                       | Zahra et al., 2011                                                       |
| Hepatocellular carcinoma         | Elevated MPs levels                                                               | Brodsky et al., 2008                                                    |
| Lung cancer                      | Elevated MPs levels                                                               | Kanazawa et al., 2003                                                   |
| Non-small cell lung cancer       | Elevated AnnexinV+-MPs                                                           | Fleitas et al., 2012                                                    |
| Melanoma                         | Elevated MPs levels                                                               | Lima et al., 2011                                                       |
| Multiple myeloma                 | Elevated MPs levels                                                               | Auwerda et al., 2011                                                    |
| Ovarian cancer                   | Elevated MPs levels; elevated CD63+ MPs comparing with benign ovarian tumors; Elevated EpCam + MPs in ascites at advanced stage | Ginestra et al., 1999; Taylor et al., 2002; Taylor, Gercel-Taylor, 2008; Rank et al., 2012; Press et al., 2012 |
| Ovarian cancer (ascites)          | Elevated epithelial cell adhesion molecule-positive MPs at advanced stages        | Press et al., 2012                                                      |
| Pancreas cancer                  | Elevated TF+ MPs                                                                  | Thaler et al., 2012                                                     |
| Prostate cancer                  | Elevated TF+ MPs; elevated MPs levels                                             | Haubold et al., 2009; Courmans et al., 2010                             |
| Different tumor types            | Elevated procoagulant MPs levels                                                  | Manly et al., 2010; Thaler et al., 2011                                 |
| Cancer with thromboembolic       | Elevated MPs levels                                                               | Zwicker Ji et al., 2009                                                 |
| complications                    |                                                                                  |                                                                           |
| Tumor surgery (tumor mass removal) | MPs decreased                                                                       | Zwicker et al., 2009; Sartori et al., 2011                              |

*references for Table 3 (Additional file 6).*
Table 4 MPs levels in the plasma and body fluids of patients with different disorders

| Disease                                      | MPs plasma levels                                                                 | Reference                                                                                                                                 |
|----------------------------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| **AUTOIMMUNE DISEASES**                      |                                                                                  |                                                                                                                                          |
| Ankylosing spondylitis                       | No differences between patient and control groups in EMPs and PMPs levels       | Sari et al., 2012                                                                                                                        |
| Anti-phospholipid syndrome                   | Elevated MPs levels; TF⁺ EMPs, monocyte-derived MPs                              | Joseph et al., 2001; Dignat-George et al., 2004; Jy et al., 2007; Vikerfors et al., 2012                                               |
| Arthritis                                    | Elevated MPs levels                                                              | Berckmans et al., 2002; Boillard et al., 2010                                                                                           |
| Acute inflammatory bowel disease             | Elevated MPs levels; elevated TF⁺ MPs                                            | Andoh et al., 2005; Palkovits et al., 2012                                                                                              |
| Behcet’s disease (systemic vasculitis)        | CD62⁺-MPs levels elevated                                                        | Macey et al., 2011                                                                                                                       |
| Cirrhosis                                    | Elevated CD31⁺/41⁺; CD11a⁺; CD4⁺; CD235a⁺; cytokeratin 18⁺ MPs                 | Rautou et al., 2012                                                                                                                      |
| Crohn’s disease                              | Elevated MPs levels comparing with normal and ulcerative colitis                 | Chamouard et al., 2005                                                                                                                   |
| Diabetes mellitus                            | Different patterns of MPs, PMPs na MMPs levels and also differences from diabetes type II pattern | Diamant et al., 2002; Sabatier et al., 2002; Shouzu et al., 2004; Ogata et al., 2005; Tramontano et al., 2010                     |
| Diabetic retinopathy                         | Increased vitreous shedding of MPs, endothelial, platelet, photoreceptor, and microglial origin | Ogata et al., 2005; 2006; Chahed et al., 2010                                                                                           |
| Diabetes type II (Diabetes mellitus)         | Elevated MPs levels; AnnexinV⁺⁺ MPs elevated                                     | Nomura et al., 1995; Sabatier et al., 2002; Nomura et al., 2004b; Tan et al., 2005; Jung et al., 2009a; Koga et al., 2005; 2006; Lenoyer et al., 2008; Nomura, 2009; Nomura et al. 2009; Bernard et al., 2009; Tsimmerman et al., 2011; Nomura et al., 2011 |
| Kawasaki disease                              | Elevated MPs levels, especially EC and T-cells derived                           | Guiducci et al., 2011; Tan et al., 2012                                                                                                  |
| Mixed connective tissue disease              | Elevated PMPs levels                                                             | Oyabu et al., 2011                                                                                                                       |
| Multiple sclerosis                           | Elevated MPs and PMPs levels                                                      | Larkin, 2001; Minagar et al., 2001; Jy et al., 2004; Jimenez et al., 2005; Sheremata et al., 2006; 2008                                  |
| Polymyositis/dermatomyositis                 | Elevated MPs and B-lymphocyte–derived MPs levels                                | Shirafuji et al., 2009; Baka et al., 2010                                                                                               |
| Psoriasis                                    | Elevated PMPs levels                                                             | Tamagawa-Mineoka et al., 2010; Pelletier et al., 2011                                                                                   |
| Rheumatoid arthritis                         | Different patterns of MPs levels in plasma; increased PMPs expressing activating markers; increased MPs in synovial fluid; increased MPs exposing complement components (C1q, serum amyloid-P) | Joseph et al., 2001; Knijff-Dutmer et al., 2002; Berckmans et al., 2002; Biro et al., 2007; Sellam et al., 2009; Messer et al., 2009; Umekita et al., 2009; van Eijk et al., 2010 |
| Sjorgen syndrome                             | Elevated MPs, PMPs, leukocyte-derived MPs levels                                 | Sellam et al., 2009                                                                                                                      |
| Systemic lupus erythematosus                 | Elevated MPs levels; PMPs levels;                                              | Combes et al., 1999; Joseph et al., 2001; Nagahama et al., 2001; Pereira et al., 2006; Sellam et al., 2009; Antwi-Baffour et al., 2010; Nielsen et al., 2011; 2012; |
| Systemic sclerosis                           | Elevated levels of Annexin V-negative MPs; Elevated annexin V⁺ CD31⁺ EMPs; elevated levels of MPs with increased loads of IgG, IgM and C1q | Guiducci et al., 2008; Nomura et al., 2008; Oyabu et al., 2011                                                                           |
| Vasculitis                                    | Elevated MPs levels                                                             | Brogan et al., 2004; Daniel et al., 2006; Erdbruegger et al., 2008                                                                        |
| **BLOOD DISORDERS**                          |                                                                                  |                                                                                                                                          |
| Aplastic anemia                              | Elevated procoagulant MPs                                                       | Hugel et al., 1999                                                                                                                       |
| Beta-thalassemia                             | Elevated MPs levels; elevated annexin V⁺ MPs from platelets and red blood cells | Pattanapanyasat et al., 2004; 2007; Habib et al., 2008; Chaichompoo et al., 2012                                                        |
| Disseminated intravascular coagulation (DIC) | Elevated MPs                                                                   | Rahman et al., 2011                                                                                                                      |
| Essential thrombocytemia                     | Elevated PMPs and EMPs levels                                                   | Trappenburg et al., 2009                                                                                                                |
Table 4 MPs levels in the plasma and body fluids of patients with different disorders (Continued)

| Disorder | Elevated MPs levels | References |
|----------|---------------------|------------|
| Haemophilia | Elevated MPs levels | Proulle et al., 2005 |
| Henoch-Schönlein purpura (HSP) | Elevated EMPs levels | Dursun et al., 2010 |
| Immune thrombocytopenic purpura (ITP) | Elevated MPs levels in acute phase and decreased in chronic phase; increased Er-Mps and PMPs levels | Jy, 1992; Tantawy et al., 2009; Sewify et al., 2013 |
| Paroxysmal nocturnal hemoglobinuria | Elevated MPs and EMPs levels | Hugel et al., 1999; Liebman, Feinstein, 2003; Simak et al., 2004; Helley et al., 2010 |
| Scott's syndrome, Castaman syndrome, Glanzmann thromboasthenia (bleeding disorders) | MPs deficiency | Sims et al., 1989; Gemmel et al., 1993; Castaman et al., 1996; Toti et al., 1996 |
| Sickle cell anemia | Elevated MPs levels; increased annexin V and PS-MPs levels; increased TF+-MPs; elevated Er-MPs | Shet et al., 2003; van Tits et al., 2009; van Beers et al., 2009; Gerotziafas et al., 2012 |
| Thrombotic thrombocytopenic purpura | Elevated MPs and PMPs levels | Galli et al., 1996; Jimenez et al., 2001 |
| **CARDIOVASCULAR DISEASES** | | |
| Acute coronary syndrome | Elevated EMPs levels; Elevated Annexin V+; EMPs and PMPs levels | Bernal-Mizrahi et al., 2003; Biassuci et al., 2012 |
| Acute pulmonary embolism | PMPs elevated | Bal et al., 2010 |
| Arterial erectile dysfunction | Elevated EMPs, MMPs levels; decreased endothelial MPs levels | La Vignera et al., 2012; Condorelli et al., 2012 |
| Cardiomyopathy | Elevated EMPs levels | Walenta et al., 2012 |
| Cardiopulmonary resuscitation | Elevated Annexin V+ MPs | Fink et al., 2011 |
| Cerebrovascular accidents | Elevated MPs levels; EMPs, PMPs elevated in patients with subarachnoid hemorrhage and acute cerebral infarction | Lee et al., 1993; Jung et al., 2009b; Lackner et al., 2010; Kuriyama et al., 2010 |
| Chronic venous unsufficiency | Elevated EMPs and MMPs levels | Georgescu et al., 2009 |
| Coronary artery disease | CD31+, Annexin V+ MPs increased | Werner et al., 2006; Amabile et al., 2011 |
| Hypertension | Elevated eMPs | Preston et al., 2003; Huang et al., 2010 |
| Myocardial infarction | Elevated MPs and PMPs levels | Stepien et al., 2012 |
| Non-valvular atrial fibrillation | PMPs elevated | Choudhury et al., 2007 |
| Pulmonary hypertension | Elevated CD62+ EMPs, leukocyte-derived MPs | Amabile et al., 2008, 2009; Bakouboula et al., 2008 |
| Thromboangiitis obliterans (Buerger's disease) | Elevated MPs during exacerabration | Damige et al., 2010 |
| Valvular atrial fibrillation | CD41+ PMPs elevated | Azzam, Zagloul, 2009 |
| Vasculites associated with anti-neutrophil antibodies (Wegener's granulomatosis; Churg-Strauss syndrome; microscopic polyangiitis) | PMPs, NMPs and EMPs elevated | Brogan et al., 2004; Daniel et al., 2006; Erdbruegger et al., 2008; Kuempers et al., 2008 |
| Deep vein thrombosis | MPs levels are not increased | Steppich et al., 2011 |
| Venous thromboembolism | Elevated EMPs | Chirinos et al., 2005 |
| Unstable angina, Cardiovascular disease, arteriosclerosis obliterans, atherosclerosis, ischemic stroke | Elevated MPs and PMPs levels; Elevated CD105+ (mesenchymal stem cell marker) after stroke, especially extensive ischemic stroke | Singh N, 1995; Mallat et al., 2001; Nomura et al., 2004a; Dymicka-Piekarska et al., 2005; Zielinska et al., 2005; Morel et al., 2005; Simak et al., 2006; Michelsen et al., 2009; Kim et al., 2012 |
| **INFECTIOUS DISEASES** | | |
| Hepatitis C | Elevated T-cell MPs levels correlated with severity of disease | Kornek et al., 2011, 2012 |
| Hepatitis C with cirrhosis | Elevated MPs levels comparing with HepC; elevated MPs from CD4+ and CD8+ T-cells | Brodsky et al., 2008 |
| HIV | Elevated MPs and EMPs levels; upregulation TF and P-selectin | Gris et al., 1996; Holme et al., 1998; Corrales-Medina et al., 2010; da Silva et al., 2011; Mayne et al., 2011 |
### Table 4 MPs levels in the plasma and body fluids of patients with different disorders (Continued)

| Disorder                                                                 | MPs Levels                                                                 | References                                                                 |
|--------------------------------------------------------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Hemolytic uremic syndrome (enterohemorrhagic *Escherichia coli* infection) | Elevated PMPs and MMPs levels                                              | Stahl et al., 2009; 2011                                                   |
| *Plasmodium falciparum* and *P. vivax* infections                        | Elevated MPs levels, Er-MPs levels                                         | Combes, 2004; 2005; Campos et al., 2010; Pankouli Mfonkeu et al., 2010; Nantakomol et al., 2011 |
| Sepsis (meningococcal)                                                   | Elevated procoagulant MPs levels                                           | Niewland et al., 2000                                                     |
| Sepsis (*Streptococcus pyogenes*)                                        | Elevated PS+-MPs levels                                                   | Oehmcke et al., 2011                                                      |
| Sepsis (pneumococcus, enterococcus, staphylococcus-associated)            | Elevated endothelial protein C-receptor+-MPs                               | Perez-Casal et al., 2011                                                  |
| Sepsis and trauma                                                        | Different patterns of MPs levels                                           | Joop et al., 2001; Ogura et al., 2001; Fujimi et al., 2003; Morel et al., 2008; Mostefai et al., 2008; Park et al., 2012 |
| Sepsis (*Candida albicans*)                                              | Elevated CD42a+ and PAC1+ PMPs                                             | Woth et al., 2012                                                         |
| Shiga-toxin induced haemolytic uraemic syndrome (HUS)                     | Elevated MPs (platelets, monocytes, granulocytes)                          | Ge et al., 2012                                                          |
| Systemic Inflammatory Response syndrome (SIRS)                           | Elevated MP levels                                                        | Ogura et al., 2004                                                        |
| **FEMALE DISORDERS**                                                     |                                                                           |                                                                            |
| Polycystic ovary syndrome (PCOS)                                         | Elevated pMPs levels in women with PCOS and hyperandrogenemia              | Koiou et al., 2011; 2013                                                  |
| Pre-eclampsia and eclampsia                                              | Different patterns of MPs levels compared with normal pregnancies: endothelial CD41MPs elevated; CD62+ MPs elevated; MMPs and CD8+ and granulocyte-derived MPs elevated | VanWijk et al., 2002; Goswami et al., 2006; Lok et al., 2008; 2009; Macey et al., 2010; Reyna-Villasmil et al., 2011; Alijotas-Reig et al., 2012 |
| Pathological pregnancies                                                 | PMPs levels decreased comparing with normal pregnancies                    | Bretelle et al., 2003; Carp et al., 2004                                  |
| Postmenopausal women taking hormone replacement therapy                  | Elevated MPs from platelets/megakaryocytes (CD61+)                         | Rank et al., 2012                                                         |
| **KIDNEY DISORDERS**                                                     |                                                                           |                                                                            |
| Chronic renal failure                                                    | CD144+ and CD146+ EMPs elevated                                           | Amabile et al., 2005; Faure et al., 2006                                  |
| Different nephropathies (nephrosclerosis; lupus nephropathy; diabetic nephropathy) | MPs levels are not changed                                                | Daniel et al., 2006                                                      |
| Hemodialysis                                                             | Elevated MPs                                                               | Daniel et al., 2006                                                      |
| Nephrotic syndrome                                                       | Lactahedrin+ ErMPs, PMPs and EMPs elevated                                 | Gao et al., 2012                                                          |
| Uremia with or w/o dialysis                                              | Elevated MPs, EMPs levels                                                  | Nomura et al., 1993; Merino et al., 2010                                  |
| **TRANSPLANTATION**                                                      |                                                                           |                                                                            |
| GVHD disease (allogeneic hematopoietic stem cell transplantation)         | Elevated MPs, PMPs levels;                                                 | Pihusch et al., 2002; Nomura et al., 2005; 2008; Trummer et al., 2011; Rank et al., 2011; De Rop et al., 2011; Wu et al., 2012 |
| Kidney transplantation                                                   | Procoagulant MPs decreased                                                 | Al-Massarani et al., 2009                                                 |
| Liver transplantation                                                    | Elevated MPs levels                                                        | Brodsky et al., 2008                                                     |
| **OTHER**                                                                |                                                                           |                                                                            |
| Acute liver injury                                                       | Elevated CD39+ MPs levels                                                  | Schmelze et al., 2012                                                    |
| Acute respiratory distress syndrome                                       | Elevated Leu and NeuMPs levels                                             | Guervilly et al., 2011                                                   |
These findings have ignited interest to MPs as possible biomarkers for diagnostics and evaluation of efficiency of a therapeutic strategy.

**MPs in cancer**

Cancer cell-derived MPs have been studied intensively in recent years, and their potential as diagnostic and prognostic tools has been described [185,186]. Tumor-derived MPs carry specific molecular markers typical for the cells of their origin, including epithelial cell adhesion molecule (EpCam), human epidermal growth receptor 2 (HER-2), CCR6, extracellular metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), and some others [118,187-191]. However, many types of cancer, such as ovarian and pancreas malignancies, exhibit no specific biomarker that makes their screening or early detection difficult. Several groups have described the transfer of oncogenic proteins and chemokines between cells by tumor-derived MPs, which leads to the horizontal spread of aggressive phenotypes among tumor cells had not expressing these proteins by themselves [90,192]. MPs from cancer cells contain a variety of cell-surface receptors, cytoskeletal components and intracellular signaling proteins [192] and the concentration of tumor-derived MPs increases during tumor progression [186,189]. Peripheral blood from cancer patients contains not only cancer cell-derived MPs but also high levels of procoagulant and platelet-derived MPs [190], which may contribute to the development of clinically relevant haemostatic abnormalities in cancer patients that is referred to as Trousseau’s syndrome [193]. Reprogramming of target cells by MPs was first described by Ratajczak et al. [122], and later on it has been shown directly that exposure of normal cells to cancer cell-derived MPs that contain fibronectin and tissue transglutaminase causes the recipient cells to acquire a transformed phenotype [194]. Moreover, it was reported that when MPs produced by cultures of different human primary tumors or established tumor cell lines were isolated and added back to the same cancer cells the growth of these cells was accelerated [90]. Finally, it was found that MPs derived from a subset of CD105+ tumor-initiating human renal carcinoma cells were able to activate endothelial cells in vitro and triggered their growth and vascularization after implantation into SCID mice [195].

MPs shed by tumor cells serve as a profound additional pathway for drug release [196]. Intensity of MP shedding and anti-cancer drug resistance by positively correlate across wide number of cell lines and drugs tested [196]. Besides, Jaiswal et al. [197] have shown that MPs derived from both ABCB1-mediated multidrug-resistant acute lymphoblastic leukemic and breast cancer cells can transfer mRNAs that encode multidrug resistance (MDR) transporter proteins into the drug-sensitive cancer cells, allowing for horizontal acquisition of drug resistance. This study also demonstrated that MPs express greater concentration of specific miRNAs as compared to their cells of origin (for example miR-451). This “non-genetic” intercellular transfer of molecular components provides an alternative pathway for circumvention of MDR. The time-dependence of P-gp transfer by MPs and increase of influx activity in MCF-7 breast cancer cells reveal the occurrence of multiple routes for extragenetic MDR acquisition by cancer cells [198].

The contribution of platelet-derived MPs to hematogeneous cancer metastasis is tied to their procoagulant activity [199]. Metastatic processes depend on the haemostatic competence of tumour cells and their capacity to initiate microvascular thrombosis [190], and MPs may promote these processes via transfer of miRNAs that encode angiogenic factors such as MMP-9, interleukin-8, VEGF [200]. Indeed, injection PMP-covered Lewis lung carcinoma cells (LLC) into syngeneic mice results in the formation of significantly more metastatic foci in the lungs of these animals as compared to mice injected only with LLC [200]. Also in prostate cancer patients elevated plasma PMP levels correlate with aggressiveness of tumors and poor clinical outcome [201].

### Table 4 MPs levels in the plasma and body fluids of patients with different disorders (Continued)

| Disorder                        | MPs level                                      | References                           |
|---------------------------------|-----------------------------------------------|-------------------------------------|
| Alzheimer's disease             | Elevated EMPs                                 | Xue et al., 2012                    |
| Atopic dermatitis               | Elevated PMPs levels                           | Tamagawa-Mineoka et al., 2009       |
| Cystic fibrosis                 | Elevated levels of granulocyte MPs in sputum  | Porro et al., 2010                  |
| (CD11a+ and CD66b+)             |                                               |                                     |
| Fabry disease                   | Elevated CD63+ MPs                             | Gelderman et al., 2007; Vedder et al., 2009 |
| Metabolic syndrome             | Different patterns of MPs levels               | Arteaga et al., 2006; Chironi et al., 2006; Agouni et al., 2008; Ueba et al., 2008; Helal et al., 2010 |
| Obstructive sleep apnea syndrome| PMPs elevated                                  | Maruyama et al., 2012               |
| Polymyalgia rheumatica          | CD31+/CD42+ EMPs elevated                      | Pirro et al., 2011                  |
| Schizophrenia                   | MPMS elevated in cerebrospinal liquid          | Mobarrez et al., 2013               |

*references for Table 4 (Additional file 7).*
MPs and vascular diseases

Platelet-derived MPs have been extensively investigated for their ability to induce coagulation and participate in thrombosis because they display PS and other negatively charged phospholipids that provide binding sites for activated coagulation factors [202]. PMPs have significantly higher (50-100x) procoagulant activity compared even to activated platelets [87]. PMPs may regulate additional vascular pathways, including activation of endothelial cells and leukocytes, stimulation of angiogenesis, and induction of apoptosis in endothelial cells [203]. MPs released by normal endothelial cells are implicated in angiogenesis, as well as bone regeneration and mineralization in vivo [204-206]. MPs originating from human atherosclerotic plaques carry mature form of tumor necrosis factor (TNF)-converting enzyme metalloprotease TACE/ADAM 17, which cleaves TNF and its receptors TNF-R1 and TNF-R2 [207]. These MPs enhance shedding of TNF from cultured human cells that overexpress TNF, as well as TNFR1 shedding from HUVEC cell lines, suggesting that TACE+ MPs regulate the inflammatory balance in culprit atherosclerotic plaque lesion [207]. Several forms of hemolytic anemia are associated with elevated levels of MPs in plasma and concomitantly with high tissue factor (TF) activity [97,208-210]. Monocyte-derived MP levels are elevated in the plasma of paroxysmal nocturnal hemoglobinuria patients, as monocytes in these individuals are fragile due to a deficiency in surface expression of CD55 and CD59 [209].

Since endothelial MPs from patients with metabolic disorders induce endothelial dysfunction in animal models [211], and elevated circulating MP levels are associated with both severity and adverse outcomes in several cardiovascular pathologies, including myocardial infarction, atherothrombosis, hypertension, and pre-eclampsia, risk stratification for these conditions now relies, in part, on the measurement of MP levels (summarized in Additional file 3).

MPs and infectious diseases

Bacterial virulence factors such as the M1 protein from \textit{S.pyogenes} and lipopolysaccharide (LPS) from \textit{E.coli} stimulate the release of procoagulant MPs from PBMCs [212,213]. A number of publications have reported that specific MP subtypes in septic patients, such as endothelium-, platelet- and monocyte-derived MPs, are associated with different etiologies of sepsis (\textit{S.pyogenes, Staphylococcus, Pneumococcus, Enterococcus}) [213,214]. Elevated MP levels are associated with systemic inflammatory response syndrome (SIRS) and hemolytic uremic syndrome caused by \textit{E.coli} infection [215,216]. It is possible that MPs produced by infected cells, or by cells exposed to bacterial virulence factors, may contribute to secondary organ dysfunction observed during these disorders. Mastronardi and colleagues [217] have reported that injection of MPs from septic shock patients into experimental animals leads to changes in the enzyme systems related to inflammation, nitrative and oxidative stress. These findings are in accordance with the results obtained by other investigators [218], which have indicated that the injection of normal rats with MPs obtained from septic rats induces hemodynamic changes and septic inflammatory responses in the heart.

ErMP levels are significantly increased in the blood of malaria patients with coma or severe malaria [184] and correlate with plasma TNF concentrations [219]. Cell-derived and \textit{Plasmodium}-derived MPs contribute to the development of fatal cerebral malaria [220-222]. In \textit{in vitro} experiments PMPs were found to bind preferentially to \textit{Plasmodium}-infected erythrocytes or iRBCs, and increase cytoadherence of iRBCs to HUVECs [222]. Moreover, it has been shown that \textit{P.falciparum} synthesizes and packages Maurer’s clefts (parasite-derived structures within the host cell cytoplasm that are thought to function as a sorting compartment between the parasite and the parasitophorous membrane [223])

\textbf{Figure 5} Potential mechanisms of MP action.
subsequently exporting them to the cytoplasm of infected erythrocytes via MPs shedding [223]. Observations on another eukaryotic parasite, L. donovani, also demonstrated that parasite-produced microvesicles are released from infected cells [224]. MPs released by bacteria Porphyromonas gingivalis that cause periodontal disease, carry lipoproteins and other proinflammatory mediators to the distant sites and contribute to progression of atherosclerosis [225,226]. Summarizing it could be concluded that in many cases MPs and exosomes released by infected host cells contain pathogen-derived antigens and virulence factors and may modulate disease progression and immune response [225-230].

Conclusion
As methods for isolating and characterizing MPs advance, it is anticipated better understanding of the mechanisms of MP formation and functional activity will be achieved in near future (a current overview of MP activity is summarized in Figure 5). Flow cytometry, fluorescent microscopy and light scattering methods will be critical for the characterization of MP preparations. A growing number of reports have demonstrated that MPs are produced by a remarkably diverse array of cell types and may alter the phenotype and behavior of different cell populations. However, despite four decades of MP research, we are just beginning to understand the contribution of MPs to disease development and pathogenesis. The association of elevated MP levels with many different pathological states makes them of particular interest for clinical research, and suggests that these tiny vesicles have great potential for the development of new diagnostic assays aimed at identifying early stages of pathological disorders and response for therapy, the creation of a novel class of therapeutics for improved intervention in a group of difficult-to-treat diseases. Future diagnostic exploitation of MPs may circumvent the need for some current invasive procedures, such as amniocentesis or chorion villus sampling for the diagnosis of prenatal disorders. Further dissection of circulating MP components and their functional roles will undoubtedly expand their usefulness as biomarkers and, in turn, as sentinels that steer investigators to more efficacious treatment options.

Additional files

Additional file 1: Range of MP sizes in different publications.
Additional file 2: References for Table 1 (Summary of some methods applied for MPs research).
Additional file 3: MP-based risk stratification of some pathological states.
Additional file 4: Supplemental Table. Changes in MP levels in peripheral blood of patients in response to treatments.

Additional file 5: References for Table 2 (MP levels in the plasma of healthy controls).
Additional file 6: References for Table 3 (MP levels in the plasma and body fluids of patients with cancer).
Additional file 7: References for Table 4 (MP levels in the plasma and body fluids of patients with different disorders).

Abbreviations
AB: Antibody; ABCA1: ATP binding cassette transporter A1; ABCB1: ATP binding cassette transporter B1; ADAM10: A disintegrin and metalloproteinase domain-containing protein 10; ARF6: ADP-ribosylation factor 6; Allo-HSCT: Allogeneic hematopoietic cell transplantation; ARFCES: Carcinogenicmybicron antigens; ASC: Allogeneic stem cell transplantation; BALF: Bronchoalveolar lavage fluid; calcine AM: Acetoxymethoxy derivative of calcine; CCR5: C-C chemokine receptor type 5; CXCL12: Chemokine (C-X-C motif) ligand 12; CXCRI4: C-X-C chemokine receptor type 4; DC: Dendritic cell; EDTA: Ethylenediaminetetraacetic acid; EM: Electronic microscopy; EGF: Epidermal growth factor receptor; EMPS: Endothelial microparticles; EP CAM: Epithelial cell adhesion molecule; Er-MPs: Erythrocyte-derived microparticles; ERK: Extracellular signal-regulated kinase; Fas: CD95; FasL: Fas ligand; FMD: Flow-mediated vasodilatation; GHD: Graf-host disease; HER2: Human epidermal growth receptor 2; H: Human immunodeficiency virus; HSP: Heat shock protein; HUEVC: Human umbilical vein endothelial cell; ICAM-1: Intercellular adhesion molecule 1; LLC: Lewis lung carcinoma; LPS: Lipopolysaccharide; MDR: Multiple drug resistance; mRNA: Messenger RNA; miRNA: microRNA; MMPs: Metalloproteinase; MPs: Microparticles; NTA: Nanoparticle tracking assay; PAF: Platelet-activating factor; PBMCs: Peripheral blood mononuclear cells; PCOS: Polycystic ovary syndrome; P-gp: P-glycoprotein; PMPs: Platelet-derived microparticles; PMNs: Polymorphonuclear neutrophils; PS: Phosphatidylserine; RNA: Ribonucleic acid; sPLA2: Secretory phospholipase A2; Pten: Phosphatase and tensin homolog; ROCK-1: Kinase; Rho-1: Associated kinase; SIRS: Systemic inflammatory response syndrome; SLE: Systemic lupus erythematosus, STAT: Signal transducer and activator of transcription; TF: Tissue factor; TLR: Toll-like receptor; TNF-α: Tumor-necrotic factor alpha; TRAIL: TNF-related apoptosis-induced ligand; TRM: Transplantation-related mortality; TS Ig101: Tumor specific antigen 101; VEGF: Vascular endothelial growth factor.

Competing interests
LD is employed by Becton Dickinson Biosciences Inc. Other authors do not have any competing interests.

Authors’ contributions
NSB and IAV wrote the first draft. EFK, MB, JNHS, EDP and LD critically approved the final manuscript. NSB and IAV wrote the first draft. EFK, MB, JNHS, EDP and LD critically approved the final manuscript. We are thankful to Luke Jasenosky and Aleksandra Gorelova (Harvard Medical School, Boston, MA, USA). We are thankful to Luke Jasenosky and Aleksandra Gorelova (Harvard Medical School, Boston, MA, USA). We are thankful to Luke Jasenosky and Aleksandra Gorelova (Harvard Medical School, Boston, MA, USA). We are thankful to Luke Jasenosky and Aleksandra Gorelova (Harvard Medical School, Boston, MA, USA). We are thankful to Luke Jasenosky and Aleksandra Gorelova (Harvard Medical School, Boston, MA, USA). We are thankful to Luke Jasenosky and Aleksandra Gorelova (Harvard Medical School, Boston, MA, USA).

Acknowledgements
We are thankful to Luke Jasenosky and Aleksandra Gorelova (Harvard University) for editorial help with the manuscript. NSB was supported by a Harvard Pilot Grant and the Immune Disease Institute, and IAV was supported by Russian Foundation for Basic Research grants 11-01517a and 11-01749a.

Author details
1Program in Cellular and Molecular Medicine, Boston Children’s Hospital, D-249, 200 Longwood Avenue, Boston, MA 02115, USA. 2Department of Pediatrics, Harvard Medical School, Boston, MA, USA. 3Institute of Chemistry and Bioanalytics, University of Applied Sciences Northwestern Switzerland (FHNW), Muttenz, Switzerland. 4Department of Biomedicine, University Hospital Basel, Basel, Switzerland. 5Division of Hematology, University Hospital Geneva, Switzerland. 6Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA. 7Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 8Thematic Research Program for Neurodegeneration, Development and Repair, School for Biomedical Sciences, The Chinese University of Hong Kong, Shatin, NT, Hong Kong. 9BD Biosciences Inc, San Jose, CA, USA. 10A.N. Belozersky Institute for Physico-Chemical Biology and Department of Cell
References

1. Conrado C, Raimondo S, Chiesi A, Ciccia F, De Leo G, Alessandro R: Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci 2013, 14:3388–3566.

2. Mathivanan S, Ji H, Simpson RJ: Exosomes: extracellular organelles important in intracellular communication. J Proteomics 2010, 73:1907–1920.

3. Bobrie A, Colombo M, Raposo G, Thery C: Eososome secretion: molecular mechanisms and roles in immune response. Traffic 2011, 12:1659–1668.

4. Chaput N, Thery C: Exosomes: immune properties and potential clinical implementations. Semin Immunopathol 2011, 33:419–440.

5. Silverman JM, Reiner NE: Exosomes and other microvesicles in infection biology: organelles with unanticipated phenotypes. Cell Microbiol 2011, 13:1–9.

6. Lai CP, Breakfield XO: Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Front Physiol 2012, 3:228.

7. Mause SF, Weber C: Microparticles: protagonists of a novel communication network for intracellular information exchange. Circ Res 2010, 107:1047–1057.

8. van der Pol E, Boeing AN, Harrison P, Sturk A, Nieuwland R: Classification, functions, and clinical relevance of extracellular vesicles. Pharmaco Rev 2012, 64:567–705.

9. Torrecillas AC, Schimacher R, Alves MJM, Cells W: Vesicles as carriers of virulence factors in parasitic protozoan diseases. Microb Infect 2012, 14:1465–1474.

10. Flamment R: Formation and fate of platelet microparticles. Blood Cells Mol Dis 2006, 36:182–187.

11. Distler JH, Huber LC, Gay S, Distler O, Meyer zum Buschenfelde KH: Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum 2005, 52:3337–3348.

12. Shet AS: Characterizing blood microparticles: technical aspects and challenges. Vasc Health Risk Manag 2010, 6:419–429.

13. Beyer C, Pisetsky DS: The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol 2010, 6:219–229.

14. Morel O, Morel N, Jesel L, Freyssinet JM, Toti F: Exosome-based immunotherapy. Cancer Immunol Immunother 2004, 53:234–239.

15. Zwaal RF, Schroit AJ: Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89:1121–1132.

16. Heijnen HF, Schilh AE, Fijten HH, Gerke CJ: Actin-based fusion and exocytosis of multivesicular bodies. Traffic 2011, 12:784–797.

17. Thery C, Bussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S: Proteomic analysis of denritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2011, 186:7309–7318.

18. Vannuccini F, Rinaldi M, Vitali E, Gatti A, Guglielmi C, Martina MC, Conese M, Maffione AB: Isolation and characterization of microparticles in spumic from cystic fibrosis patients. Respir Res 2010, 11:54.

19. Philippova M, Suter Y, Toggeleier S, Schoenberger AW, Jordt MB, Kyrilakakis E, Erne P, Resnik T: Cd2adherin is present on endothelial microparticles and is elevated in plasma in early atherosclerosis. Eur J Arteriovasc Surg 2011, 32:760–771.

20. Mvar-Bekoa A, Suita V, Janss A, Heintze H, Meissner L, Mugaugq C, Igelic A, Gerasimova H, Kralj-Ilgovic V: Isolated microparticles from peripheral blood and blood fluids as observed by scanning electron microscopy. Blood Cells Mol Dis 2010, 44:307–312.

21. Burger D, Montezano AC, Nishigaki N, Deli MA, Heuck AF, Touyz RM: Endothelial microparticle formation by angiotensin II via Ang II Receptor type II/ NADPH oxidase/Rho kinase kinases pathways targeted to lipid rafts. Arterioscler Thromb Vasc Biol 2011, 31:1189–1190.

22. Miquel L, Sanglier S, Schaeffer C, Potier N, Mauveuix L, Van Dorsselaer A: Microparticles: a new tool for plasma membrane sub-cellular proteomic. Subcell Biochem 2007, 41:23–34.

23. Smalley DM, Levy K: Plasma-derived microparticles for biomarker discovery. Clin Lab 2008, 54:67–79.
45. Streem JG, Barran PE, Mackay CL, Weich S, Balmforth C, Walsh TS, Chalmers RT, Webb DJ, Dear JW: Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med 2012, 10:5.

46. van der Pol E, Van Gemert MJ, Sturk A, Neuvla land R, Van Leeuwen TG: Single vs swarm detection of microparticles and exosomes by flow cytometry. J Thromb Haemost 2012, 10:819–995.

47. Iy C, Hirtzmann KX, Ahn YS: Microparticle size and its relation to composition, functional activity, and clinical significance. Semin Thromb Hemost 2010, 36:876–880.

48. Rubin O, Crettaz D, Tissot JD, Lion N: Pre-analytical and methodological challenges in red cell blood microparticle proteomics. J Thromb Haemost 2010, 8:121–8.

49. Xu Y, Nakane N, Mauren-Spierle J: Novel test for microparticles in platelet-rich plasma and platelet concentrates using dynamic light scattering. Transfusiol 2011, 51:363–70.

50. Tessa laar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S: Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007, 5:520–527.

51. Manly DA, Wang J, Glover SL, Kasthuri R, Liebman HA, Key NS, Mackman N: Non-cancerous tissue factor activity in patients with venous thromboembolism. Thromb Res 2010, 125:511–512.

52. Zwicker JI: Impedance-based flow cytometry for the measurement of microparticles. Thromb Res 2007, 125:131–132.

53. Zwicker JI, Lacroix R, Dignat-George F, Furie BC, Furie B: Detection and quantitation of microparticles: direct visualization and distinction from platelet-derived microparticles. Blood 2011, 117:1111–1121.

54. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

55. Berckmans RJ, Sturk A, Van Tienen LM, Schaap MC, Nieuwland R: Megakaryocyte-derived microparticles in blood. Blood Rev 2011, 26:465–479.

56. Barteneva N, Gueorguieva E, Ulevitch RJ: Analysis of platelet-derived microparticles reveals differences in their phospholipid composition and cholesterol content between healthy individuals and patients with rheumatoid arthritis. Arthritis Rheum 2010, 62:880–890.

57. Messer L, Alsheikh G, Freyssinet J, Zobairi F, Leray I, Gottenberg JE, Sibilia J, Ott-Jefanau daki F, Wachsmann D: Microparticle-induced release of B-lymphocyte regulators by rheumatoid synovocytes. Arthritis Res Ther 2009, 11:940.

58. Berckmans RJ, Neuvla land R, Boeing AN, Romijn FP, Hack CE, Stark A: Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001, 85:639–646.

59. Flaimana hofft, Dills JR, Richardson J, Alden E, Panel-Hett SB, Vattin et E, Klement GS, Sofa-Vivier M, Italiano JE, Fr Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood 2009, 113:1112–1121.

60. Aken MM, Gardner C, Harrison P, Weilb erg AS: Differential contributions of monocye and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost 2011, 9:2251–2261.

61. Berckmans RJ, Neuvla land R, Boeing AN, Romijn FP, Hack CE, Stark A: Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001, 85:639–646.

62. Flaimana hofft, Dills JR, Richardson J, Alden E, Panel-Hett SB, Vattin et E, Klement GS, Sofa-Vivier M, Italiano JE, Fr Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood 2009, 113:1112–1121.

63. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

64. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

65. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

66. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

67. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

68. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

69. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

70. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

71. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

72. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

73. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

74. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

75. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

76. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

77. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

78. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

79. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

80. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

81. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

82. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

83. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

84. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

85. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

86. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.

87. Sijander PR, Platelet-derived microparticles—an updated perspective. Thromb Res 2011, 127:530–533.
89. Del Conde I, Shrimpton CN, Thagraraj P, Lopez JA: Tissue factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2006, 106:1604–1611.

90. Al-Nedawi K, Meehan K, Micallef I, Jhotak V, May L, Guha A, Rak J: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008, 10:119–124.

91. Daleke DL: Regulation of transbilayer plasma membrane phospholipid asymmetry. J Lipid Res 2003, 44:235–242.

92. Bevers EM, Comfurius P, Dekkers DW, Harmsma M, Zwaal RF: Transmembrane phospholipid distribution in blood cells: control mechanisms and pathophysiological significance. Biochim Biophys Acta 1998, 3799:973–986.

93. Perez-Puerta S, Marker PH, Key NS: Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry A 2007, 71:38–45.

94. Rukoyatka N, Begonia AJ, Geiger J, Eigenbauer M, Walter U, Gambaryan S: Phosphatidylserine surface expression and integrin alpha IIb beta3 activity on thrombin/convulxin stimulated platelets/particles of different sizes. Br J Haematol 2009, 144:691–692.

95. Key NS: Analysis of tissue factor positive microparticles. Thromb Res 2010, 125:542–545.

96. Sijander P, Fardamle RW, Feige MA, Comfurius P, Kos S, Bevers EM, Heemskerk JW: Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol 2001, 21:618–627.

97. Svet AS, Arcas D, Gupta K, Hess ML, Rausch DJ, Saba N, Koopmeiners S, Key NS, Hebbel RP: Sickle blood contains tissue factor positive microparticles derived from endothelial cells and monocytes. Blood 2003, 102:2678–2683.

98. Arnaile N, Guerin AM, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London S, Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners S, Key NS, Hebbel RP: Sickle blood contains tissue factor positive microparticles derived from endothelial cells and monocytes. Blood 2003, 102:2678–2683.

99. Lentz BR: Identification of Tim4 as a phosphatidylserine receptor. Proc Natl Acad Sci USA 2001, 98:6407–6411.

100. Muralidharan-Chari V, Hoover H, Clancy J, Schweitzer J, Suckow MA, Perez-Pujol S, Marker PH, Key NS: Analysis of tissue factor positive microparticles. Thromb Res 2010, 125:542–545.

101. Matsuda T: Sphingomyelinase activity triggers microparticle release from glial cells. J Biol Chem 2009, 284:3380–3386.

102. Teshuva ME, Diamant M, Peppers EG, Hoek FJ, Heine RJ, Stuik A, Newland R: Postnatal changes in phospholipid composition of circulating microparticles are not associated with coagulation activation. Thromb Res 2001, 130:115–121.

103. Freyssinet JM: Cellular microparticles: What are they bad or good for? J Thromb Haemost 2003, 1:1655–1662.

104. Barreto KD, Hoekstra LB, Linde P, van der Lugt A, van der Giessen EM, Koster TS, Koster IK, Tanke HJ, Savelkoul PH, van der Poll T: Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int 2012, 82:412–427.


133. Hergenreider E, Heydt S, Treguer K, Boettrig T, Horrevoets AJS, Zeiher AM, Scheffler MP, Franckais AS, Yin X, Mayr M, Braun T, Utech C, Boon RA, Dimmeler S. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012, 14:249–256.

134. Watanabe J, Marathe GK, Neilson PO, Weyth AS, Harrison RA, Murphy RC, Zimmermann GA, McIntyre TM. Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles. J Biol Chem 2003, 278:33161–33168.

135. Cardo LJ, Wilder D, Salata J. Neutrophil priming caused by cell membranes and microparticles in packed red blood cell units, is abrogated by leukocyte depletion at collection. Transfus Apher Sci 2008, 38:117–125.

136. Fujimi S, Ogura H, Tanaka H, Koh T, Hostosubu H, Nakamori Y, Kuwagata Y, Shimazu T, Sugiimoto H. Increased production of leukocyte microparticles with enhanced expression of adhesion molecules from activated polymorphonuclear leukocytes in severely infected patients. J Trauma 2003, 54:114–119.

137. Press JZ, Reyes M, Pitter SJ, Pennil C, Garcia R, Goff BA, Hanash SM, Swisher S, Schett G, Distler O. Transcription. A, Weber C. Hristov M, Koeppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober M, Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C, Arancia G, Gentile M, Seregni E, Valenti R, Ballabio G, Belli F, Leo E, Parmiani G, Himber J, Riederer MA, Nemerson Y. hsa-miR-155 primes human monocytes to promote endothelial microvesicle-dependent transendothelial migration. J Thromb Haemost 2005, 3:888–896.

138. Rautou PE, Leroyer AS, Ramkhelawon B, Devue C, Duflaut D, Vion AC, Press JZ, Reyes M, Pitteri SJ, Pennsylvania C, Garcia R, Goff BA, Hanash SM, Swisher S, Schett G, Distler O. Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles. J Biol Chem 2003, 278:33161–33168.

139. Rozmyslowicz T, Majka M, Kijowski J, Murphy SL, Conover DO, Poncz M, Rautou PE, Leroyer AS, Ramkhelawon B, Devue C, Duflaut D, Vion AC, Press JZ, Reyes M, Pitteri SJ, Pennsylvania C, Garcia R, Goff BA, Hanash SM, Swisher S, Schett G, Distler O. Transcription. A, Weber C. Hristov M, Koeppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober M, Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C, Arancia G, Gentile M, Seregni E, Valenti R, Ballabio G, Belli F, Leo E, Parmiani G, Himber J, Riederer MA, Nemerson Y. hsa-miR-155 primes human monocytes to promote endothelial microvesicle-dependent transendothelial migration. J Thromb Haemost 2005, 3:888–896.

140. Abid Hussein MN, Neuwand R, Hau CM, Evers LM, Meesters EW, Stuk A. Cell-derived microparticles contain caspase 3 in vitro and in vivo. J Thromb Haemost 2005, 3:888–896.

141. Abid Hussein MN, Neuwand R, Hau CM, Evers LM, Meesters EW, Stuk A. Cell-derived microparticles contain caspase 3 in vitro and in vivo. J Thromb Haemost 2005, 3:888–896.

142. Alphonse N, Folkert E, Schifferli JA: Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One 2010, 5:e11803.

143. Alphonse N, Folkert E, Schifferli JA: Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One 2010, 5:e11803.

144. Aliotta JM, Pereira M, Johnson KW, De Paz N, Dooner MS, Puente N, Ayala C, Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, Zaccheddu A, Colone M, Giesen PL, Rauch BA, Bohrmann B, Kling D, Rogue M, Fallon JT, Badimon JJ, Gasser O, Schifferli JA: Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One 2010, 5:e11803.

145. Aliotta JM, Pereira M, Johnson KW, De Paz N, Dooner MS, Puente N, Ayala C, Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, Zaccheddu A, Colone M, Giesen PL, Rauch BA, Bohrmann B, Kling D, Rogue M, Fallon JT, Badimon JJ, Gasser O, Schifferli JA: Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One 2010, 5:e11803.
173. Amable N, Heiss C, Chang V, Angelis FS, Damon L, Rame EJ, McGlothlin D, Grossman W, De Marco T, Yehgahyans Y: Increased CD62e + endothelial microparticles levels predict poor outcome in pulmonary hypertension patients. J Heart Lung Transplant 2009, 28:1081–1086.

174. Nokazi T, Sugiyama S, Sugamura K, Ohta K, Matsuwa Y, Konishi M, Matsubara J, Niyama Y, Sumida H, Matsumoto K, Iinouchi H, Ogawa H: Prognostic value of endothelial microparticles in patients with heart failure. Eur J Heart Fail 2010, 12:1223–1228.

175. Sinning JM, Losch J, Walenta K, Boehm M, Nickenig G, Werner N: Circulating CD31+/Annexin V + microparticles correlate with cardiovascular outcomes. Eur Heart J 2011, 32:2034–2041.

176. Sellam J, Poulou V, Jungel A, Itthar M, McClellan RC, Gottenberg JE, Toti F, Barteneva N, Sheremata WA, Jy W, Delgado S, Minagar A, McLarthy J, Ahn Y: Increased microparticle levels predict poor outcome in pulmonary hypertension. Circ Res 2011, 104:145–149.

177. Nakamura S, Omoto S, Yokoi T, Fujita S, Ozasa R, Eguchi N, Shouzu A: Enhanced accumulation of circulating platelet-derived microparticles in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 2010, 850:737–740.

178. Martinez MC, Andrianistiohna R: Microparticles in angiogenesis: therapeutic potential. Circ Res 2011, 109:110–119.

179. Morel O, Jesel L, Hugel B, Douchet MP, Zupan M, Chauvin M, Freyssinet JM: Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 2009, 56(6):597–604.

180. Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, Tetta C, Boulanger CM, Nalbone G: Circulating tumour-derived membrane vesicles: mediators of extracellular communication during cancer progression. J Cell Sci 2010, 123:1603–1611.

181. Nomura S, Omoto S, Yokoi T, Fujita S, Ozasa R, Eguchi N, Shouzu A: Increased levels of circulating microparticles in primary Sjögren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther 2009, 11:R56.

182. Shcheretam WA, Jy W, Delgado S, McClellan JW, Rame EJ, McGlothlin D, Barteneva N, Sheremata WA, Jy W, Delgado S, Minagar A, McLarthy J, Ahn Y: Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 2003, 102(16):5346–5356.

183. Arthritis Res Ther 2009, 11:R56.

184. Antonyak MA, Li B, Boroughs LK, Johnson JL, Drusko J, Bryant KL, Holowka DA, Cerone RA: Cancer cell-derived microparticles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci USA 2011, 108:4852–4857.

185. Buller HR, Van Doormaal FF, Van Sluis GL, Kamphuisen PW: Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007, 5:246–254.

186. Antonyak MA, Li B, Boroughs LK, Johnson JL, Drusko J, Bryant KL, Holowka DA, Cerone RA: Cancer cell-derived microparticles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci USA 2011, 108:4852–4857.

187. Buller HR, Van Doormaal FF, Van Sluis GL, Kamphuisen PW: Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007, 5:246–254.

188. Antonyak MA, Li B, Boroughs LK, Johnson JL, Drusko J, Bryant KL, Holowka DA, Cerone RA: Cancer cell-derived microparticles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci USA 2011, 108:4852–4857.

189. Arthritis Res Ther 2009, 11:R56.

190. Antonyak MA, Li B, Boroughs LK, Johnson JL, Drusko J, Bryant KL, Holowka DA, Cerone RA: Cancer cell-derived microparticles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci USA 2011, 108:4852–4857.

191. Arthritis Res Ther 2009, 11:R56.
virulence factors leads to the release of pro-coagulant and pro-inflammatory microparticles. *Cell Microbiol* 2012, 14:107–119.

214. Perez-Calas M, Thompson V, Downey C, Welters I, Wynccoli D, Thachil J, Toh CH: The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis. *Crit Care* 2011, 15:R195.

215. Ogura H, Tanaka H, Kih T, Fujita K, Furüm T, Nakamoto Y, Hosotsubo H, Kiyama T, Shimizu T, Sugimoto H: Enhanced production of endothelial microparticles with increased binding to leukocytes in patients with severe systemic inflammatory response syndrome. *J Trauma* 2004, 56:823–830.

216. Stahl AL, Sartz L, Karpman D: Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic *Escherichia coli*-induced hemolytic uremic syndrome. *Blood* 2011, 117:9503–9513.

217. Mastronardi ML, Mostefai HA, Meziani F, Martinez MC, Asfar P, Andriantsitohaina R: Circulating microparticles from septic shock patients exert differential tissue expression of enzymes related to inflammation and oxidative stress. *Crit Care Med* 2011, 39:1739–1746.

218. Morina S, Martinez CM, Baron-Menguy C, Burban M, de la Bourdonnaye M, Fizanne L, Pierrot M, Cales P, Henriot D, Andriantsitohaina R, Mercat A, Asfar P, Meziani F: Detrimental hemodynamic and inflammatory effects of microparticles originating from septic rats. *Crit Care Med* 2009, 37:2045–2050.

219. Combes V, Taylor TE, Juhan-Vague I, Mgele J, Mwenenecha J, Tembo M, Grau GE, Molynieux ME: circulating endothelial microparticles in malawian children with severe falciparum malaria complicated with coma. *JAMA* 2004, 291:2542–2544.

220. Combes V, El-Assaad F, Faille D, Jambou R, Hunt NH, Grau GE: Microvesiculation and cell interactions at the brain-endothelial interface in cerebral malaria pathogenesis. *Progr Neurobiol* 2010, 91:140–151.

221. Bhattacharjee S, Van Ooij C, Balu B, Adams JH, Haldar K: *Leishmania* Maurer’s clefts of *Plasmodium falciparum* are secretory organelles that concentrate virulence protein reporters for delivery to the host erythrocyte. *Blood* 2008, 111:2418–2426.

222. Faille D, Combes V, Mitchell AJ, Fontaine A, Juhan-Vague I, Assisi MC, Chimim N, Fusai T, Grau GE: Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium. *FASEB J* 2009, 23:3449–3458.

223. Spycher C, Rug M, Klonis N, Furgon DJ, Cowman A, Zuck H-P, Tilley L: Genesis of and trafficking to the Maurer’s clefts of *Plasmodium falciparum* infected erythrocytes. *Mol Cell Biol* 2006, 26:4074–4085.

224. Silverman JM, Clos J, De Oliveira CC, Shvivany O, Fang Y, Wang C, Foster L, Reiner NE: An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages. *J Cell Sci* 2010, 123:842–852.

225. Kuramitsu HK, Kang IC, Q M: Interactions of *Porphyromonas gingivalis* with host cells: implications for cardiovascular diseases. *J Periodontol* 2003, 74:865–89.

226. Pussinen PJ, Mattila K: Periodontal infection and atherosclerosis: mere associations? *Curr Opin Lipidol* 2004, 15:583–588.

227. Nandan D, Tran T, Thinh E, Silverman JM, Lopez M: Identification of Leishmania fructose-1,6-biphosphate aldolase as a novel activator of host macrophage Src homology 2 domain containing protein tyrosine phosphatase SHP-1. *Biochem Biophys Res Commun* 2007, 364:601–607.

228. Gomez MA, Contreras I, Halle M, Tremblay ML, McMaster RW, Olivier M: *Leishmania* GP63 alters host signalling through cleavage-activated protein tyrosine phosphatases. *Sci Signal* 2009, 2ra58.

229. McCal I, Matlaszewski G: Localization and induction of the A2 virulence factor in Leishmania: evidence that A2 is a stress response protein. *Mol Microbiol* 2010, 77:518–530.

230. Oliveira DL, Freire-de-Lima CG, Nosanchuk JD, Casadevall A, Rodrigues ML, Nirmricher L: Extracellular vesicles from *Cryptococcus neoformans* modulate macrophage functions. *Infect Immun* 2010, 78:1601–1609.